DNA Aptamer Assembly as a Vascular Endothelial Growth Factor Receptor Agonist

Nucleic Acid Therapeutics

Volumn 25, Issue 5, 2015, Pages 227-234

  Ramaswamy, Vidhya ^a   Monsalve, Adam ^a   Sautina, Larysa ^b   Segal, Mark S ^b,c   Dobson, Jon ^a,d   Allen, Josephine B ^a,d  

^a J Crayton Pruitt Family Department of Biomedical Engineering   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; CD134 ANTIGEN; DNA; ENDOTHELIAL NITRIC OXIDE SYNTHASE; PROTEIN KINASE B; RECEPTOR SUBUNIT; RNA; VASCULOTROPIN RECEPTOR 2; KDR PROTEIN, HUMAN; NOS3 PROTEIN, HUMAN;

ARTICLE; BINDING AFFINITY; CELL FUNCTION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; LIGAND BINDING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING; UPREGULATION; AGONISTS; ANGIOGENESIS; CELL CULTURE; DRUG EFFECTS; METABOLISM; PHOSPHORYLATION; PRECLINICAL STUDY; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL;

APTAMERS, NUCLEOTIDE; CELLS, CULTURED; DRUG EVALUATION, PRECLINICAL; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84941888936     PISSN: 21593337     EISSN: 21593345     Source Type: Journal    
DOI: 10.1089/nat.2014.0519     Document Type: Article

References (29)

1. Gestwicki JE, CW Cairo, LE Strong, KA Oetjen and LL Kiessling. (2002). Influencing receptor-ligand binding mechanisms with multivalent ligand architecture. J Am Chem Soc 124:14922-14933.
2. Lee K, EA Silva and DJ Mooney. (2011). Growth factor delivery-based tissue engineering: general approaches and a review of recent developments. J R Soc Interface 8:153-170.
3. Douglas MR, KC Morrison, SJ Jacques, WE Leadbeater, AM Gonzalez, M Berry, A Logan and Z Ahmed. (2009). Off-target effects of epidermal growth factor receptor antagonists mediate retinal ganglion cell disinhibited axon growth. Brain 132:3102-3121.
4. Jayasena SD. (1999). Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin Chem 45:1628-1650.
5. Hermann T and DJ Patel. (2000). Biochemistry - adaptive recognition by nucleic acid aptamers. Science 287:820-825.
6. Tuerk C and L Gold. (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249:505-510.
7. Brody EN and L Gold. (2000). Aptamers as therapeutic and diagnostic agents. J Biotechnol 74:5-13.
8. Ellington AD and JW Szostak. (1990). In vitro selection of RNA molecules that bind specific ligands. Nature 346: 818-822.
9. White RR, BA Sullenger and CP Rusconi. (2000). Developing aptamers into therapeutics. J Clin Invest 106:929-934.
10. Morris KN, KB Jensen, CM Julin, M Weil and L Gold. (1998). High affinity ligands from in vitro selection: complex targets. Proc Natl Acad Sci U S A 95:2902-2907.
11. Wang C, M Zhang, G Yang, D Zhang, H Ding, H Wang, M Fan, B Shen and N Shao. (2003). Single-stranded DNA aptamers that bind differentiated but not parental cells: subtractive systematic evolution of ligands by exponential enrichment. J Biotechnol 102:15-22.
12. Keefe AD, S Pai and A Ellington. (2010). Aptamers as therapeutics. Nat Rev Drug Discov 9:537-550.
13. Ng EW, DT Shima, P Calias, ET Cunningham, Jr., DR Guyer and AP Adamis. (2006). Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 5:123-132.
14. Ruckman J, LS Green, J Beeson, S Waugh, WL Gillette, DD Henninger, L Claesson-Welsh and N Janjic. (1998). 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGFinduced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 273: 20556-20567.
15. White RR, S Shan, CP Rusconi, G Shetty, MW Dewhirst, CD Kontos and BA Sullenger. (2003). Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2. Proc Natl Acad Sci U S A 100:5028-5033.
16. Ferrara N, HP Gerber and J LeCouter. (2003). The biology of VEGF and its receptors. Nat Med 9:669-676.
17. Mori Y, S Nagaoka, H Takiuchi, T Kikuchi, N Noguchi, H Tanzawa and Y Noishiki. (1982). A new antithrombogenic material with long polyethyleneoxide chains. ASAIO J 28:459-463.
18. Leppänen V-M, AE Prota, M Jeltsch, A Anisimov, N Kalkkinen, T Strandin, H Lankinen, A Goldman, K Ballmer-Hofer and K Alitalo. (2010). Structural determinants of growth factor binding and specificity by VEGF receptor 2. Proc Natl Acad Sci U S A 107:2425-2430.
19. Gonzaga F, R D'Souza and MA Brook. (2011). Oriented crystallization of ultra-thin (2 nm) gold nanoplatelets inside a reactive hydrophobic polymeric matrix. Soft Matter 7: 722-729.
20. Dollins CM, S Nair, D Boczkowski, J Lee, JM Layzer, E Gilboa and BA Sullenger. (2008). Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer. Chem Biol 15:675-682.
21. Ullrich A and J Schlessinger. (1990). Signal transduction by receptors with tyrosine kinase activity. Cell 61:203-212.
22. Xiao Z, D Shangguan, Z Cao, X Fang and W Tan. (2008). Cell-specific internalization study of an aptamer from whole cell selection. Chemistry 14:1769-1775.
23. Zhang K, K Sefah, L Tang, Z Zhao, G Zhu, M Ye, W Sun, S Goodison and W Tan. (2012). A novel aptamer developed for breast cancer cell internalization. ChemMedChem 7:79-84.
24. Koch S and L Claesson-Welsh. (2012). Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harb Perspect Med 2:a006502.
25. Manning BD and LC Cantley. (2007). AKT/PKB signaling: navigating downstream. Cell 129:1261-1274.
26. Hers I, EE Vincent and JM Tavaré. (2011). Akt signalling in health and disease. Cell Signal 23:1515-1527.
27. Fujio Y and K Walsh. (1999). Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J Biol Chem 274:16349-16354.
28. Gerber HP, A McMurtrey, J Kowalski, M Yan, BA Keyt, V Dixit and N Ferrara. (1998). Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 273:30336-30343.
29. Koolwijk P, E Peters, B van der Vecht, C Hornig, HA Weich, K Alitalo, DJ Hicklin, Y Wu, L Witte and VW van Hinsbergh. (2001). Involvement of VEGFR-2 (kdr/flk-1) but not VEGFR-1 (flt-1) in VEGF-A and VEGF-C-induced tube formation by human microvascular endothelial cells in fibrin matrices in vitro. Angiogenesis 4:53-60.